Befejeződött2. fázis
Magrolimab plus intensive chemotherapy in newly diagnosed “ELN intermediate or poor-risk” AML patients intended to undergo allogeneic stem cell transplantation, a Phase 2, Single-arm, Open-Label Study (MAGROLIC)
Key facts
- Where
- Aachen, Augsburg, Bamberg, Berlin, Chemnitz, Cottbus, Dresden, Duisburg, Erlangen, Frankfurt Am Main, Halle (Saale), Heidelberg, Jena, Kiel, Koblenz, Leipzig, Mannheim, Muenster, Regensburg, Riesa, Sindelfingen és Stuttgart, NémetországSee the 22 sites
- Phase
- 2. fázis
Where in Németország
- Universitaetsklinikum Aachen AöRAachen, NémetországNo longer taking part
- University Hospital AugsburgAugsburg, NémetországNo longer taking part
- Sozialstiftung BambergBamberg, NémetországNo longer taking part
- HELIOS Klinikum Berlin Buch GmbHBerlin, NémetországNo longer taking part
- Klinikum Chemnitz gGmbHChemnitz, NémetországNo longer taking part
- Carl Thiem Klinikum gGmbHCottbus, NémetországNo longer taking part
- Technische Universität DresdenDresden, NémetországNo longer taking part
- HELIOS Klinikum Duisburg GmbHDuisburg, NémetországNo longer taking part
- Universitaetsklinikum Erlangen AöRErlangen, NémetországNo longer taking part
- Goethe University FrankfurtFrankfurt Am Main, NémetországNo longer taking part
- Martin-Luther-Universitaet Halle-WittenbergHalle (Saale), NémetországNo longer taking part
- Universitaetsklinikum Heidelberg AöRHeidelberg, NémetországNo longer taking part
- University Hospital Jena KöRJena, NémetországNo longer taking part
- University Medical Centre Schleswig-HolsteinKiel, NémetországNo longer taking part
- Gemeinschaftsklinikum Mittelrhein gGmbHKoblenz, NémetországNo longer taking part
- Universitaet LeipzigLeipzig, NémetországNo longer taking part
- Universitaetsklinikum Mannheim GmbHMannheim, NémetországNo longer taking part
- Westfaelische Wilhelms-Universitaet MuensterMuenster, NémetországNo longer taking part
- Barmherzige Brueder gemeinnuetzige Krankenhaus GmbHRegensburg, NémetországNo longer taking part
- Elblandkliniken Stiftung & Co.KGRiesa, NémetországNo longer taking part
- Kliniken SindelfingenSindelfingen, NémetországNo longer taking part
- Robert Bosch Gesellschaft fuer medizinische Forschung mbHStuttgart, NémetországNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Leipzig
- Trial code
- EU 2022-502040-13-00
- Record updated
- 2023. július 18.
- Original description
Best CR/CRi/CRh during induction chemotherapyRead full original descriptionShow less
Best CR/CRi/CRh during induction chemotherapy
Inclusion: AML or MDS-IB-2 according to WHO 2022 criteria; “Intermediate or adverse risk” ELN 2022 category (for both MDS or AML); Intention to undergo intensive chemotherapy (CPX-351 or “7+3”) followed by allogeneic HSCT.
Exclusion: Not eligible for intensive chemotherapy; Any prior treatment for AML or high-risk MDS (including magrolimab) except hydoxyurea; Inadequate cardiac, pulmonary, renal, hepatic function; Active and uncontrolled infection; Diagnosed or treated for another malignancy within 1 year before registration; Harboring a FLT3mut, regardless of FLT3-ITD or FLT3-TKD mutation status; Acute promyelocytic leukemia (APL); ECOG ≥3.